OR WAIT 15 SECS
The new CMO combines SK Biotek in Korea, SK Biotek in Ireland, and AMPAC Fine Chemicals in the US to form SK Pharmteco.
SK Holdings, the holding company of South Korea's SK Group, announced it has combined SK Biotek in Korea, SK Biotek in Ireland, and AMPAC Fine Chemicals (AFC) in the United States to form SK Pharmteco, a new Sacramento, CA-based contract manufacturing organization (CMO) for pharmaceutical customers. The company will be headed by Aslam Malik, former CEO of AFC, as CEO.
"The creation of Pharmteco provides an excellent base upon which we will grow our global CMO business," said Malik in a Sept. 16, 2019 press release. "We are grateful for the strong support of SK Holdings and with our demonstrated Quality, six production plants, one analytical testing facility, and a wide array of enabling technologies, we are able to offer our unique value proposition to customers on an expanded global scale.”
According to the press release, SK Pharmteco has a CMO production capacity of over 1000 m3 with plans to expand within the next few years.